Akebia Unveils New Public Offering of Common Stock
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a dedicated biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, has publicly announced the pricing details of its recent offering. This offering involves 25 million shares of common stock, each priced at $2.00, aiming to generate significant proceeds that support ongoing initiatives.
The expected gross proceeds from this offering, calculated before the deduction of underwriting fees and other associated expenses, stand at around $50 million. This funding will further bolster Akebia's mission to advance treatments and research for kidney-related health issues.
Key Details of the Offering
As part of the offering, Akebia has provided underwriters with a 30-day option to acquire an additional 3.75 million shares at the offering price. The culmination of this offering is anticipated, subject to customary conditions being met.
Leerink Partners and Piper Sandler & Co. are leading the underwriting team as joint bookrunning managers. In addition, BTIG, LLC acts as the lead manager, while H.C. Wainwright & Co. also joins as a co-manager for this initiative.
Regulatory Compliance and Statement Details
The shares offered are done so in accordance with a shelf registration statement, which was filed and approved by the Securities and Exchange Commission (SEC). This ensures that all regulatory protocols are adhered to, thereby safeguarding investor interests and company obligations.
The offering will proceed with full transparency, as a preliminary prospectus outlining its terms has already been filed with the SEC. Once finalized, this documentation will be readily accessible to interested parties, ensuring informed investment decisions.
Enhancing Akebia's Commitment to Kidney Health
Akebia Therapeutics stands firm in its commitment to advancing the treatment of kidney diseases. Founded in 2007 and headquartered in Cambridge, Massachusetts, the company has continuously focused its resources on impactful research and development.
By obtaining additional capital through this stock offering, Akebia aims to accelerate its projects and initiatives, targeting innovations that can lead to improved patient outcomes and a brighter future for those suffering from kidney ailments.
About Akebia Therapeutics
As a fully integrated biopharmaceutical company, Akebia Therapeutics is resolute in its mission to enhance the lives of individuals impacted by kidney disorders. Their ongoing research and product development reflect a dedication to discovering and delivering effective treatments.
Investor Relations and Contact Information
Investors and interested individuals can direct inquiries to Akebia's contact personnel for further information on the offering and corporate developments. Mercedes Carrasco serves as a valuable point of contact via email.
Frequently Asked Questions
What is the purpose of Akebia's stock offering?
The stock offering is designed to raise funds that will support Akebia's initiatives for research and development focused on kidney health.
How many shares are being offered?
Akebia is offering a total of 25 million shares, with an additional option for underwriters to purchase more.
Who is managing the offering?
Leerink Partners and Piper Sandler & Co. serve as joint bookrunning managers, supported by BTIG, LLC and H.C. Wainwright & Co.
What will the funds from the offering be used for?
The proceeds will primarily be allocated toward advancing Akebia's research and product development efforts in the kidney disease space.
How can investors receive more information?
Investors may seek additional details through Akebia’s prospectus, or by contacting their investor relations team directly.
